News

  • Mon Jan 02 2023

    Coegin Pharma raises 25 mSEK

    Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new issue

    Read full article
  • Fri Dec 16 2022

    Rallybio publishes promising results with technology aquired from Prophylix Pharma

    American biotech company Rallybio publishes proof-of-concept data from animal studies with technology aquired from Tromsø-based Prophylix Pharma

    Read full article
  • Tue Dec 06 2022

    Nykode Therapeutics announces clinical collaboration with MSD

    Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.1

    Read full article
  • Wed Nov 23 2022

    Heimdall Power partners with Lede to enable green hydrogen production

    Heimdall Power announces that they have just signed a contract with the Norwegia

    Read full article
  • Fri Mar 04 2022

    Coegin Pharma merges with Follicum

    Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum.

    Read full article
  • Thu Jul 08 2021

    Bergenbio receives FDA fast track designation for bemcentinib

    Read full article
  • Tue May 18 2021

    APIM Therapeutics completes private placement and enters phase-2

    APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The procee

    Read full article
  • Tue May 11 2021

    APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer

    APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phas

    Read full article
  • Wed May 05 2021

    Arxx Therapeutics secures NOK110

    APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phas

    Read full article
  • Tue Mar 23 2021

    Heimdall Power raises NOK 155 mill

    The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power A

    Read full article

Read more about our work

  • Approach

    Reliability is at the core of what we do

    Visit page
  • Life Sciences

    We invest in a healthier future

    Visit page
  • Technology, Energy and Sustainability

    We are conscious of our responsibility

    Visit page